Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 87–97 | Cite as

Sirtuin 1: A Target for Kidney Diseases

  • Lili Kong
  • Hao Wu
  • Wenhua Zhou
  • Manyu Luo
  • Yi Tan
  • Lining Miao
  • Lu Cai
Open Access
Review Article

Abstract

Sirtuin 1 (SIRT1) is an evolutionary conserved NAD+-dependent histone deacetylase that is necessary for caloric restriction-related lifespan extension. SIRT1, as an intracellular energy sensor, detects the concentration of intracellular NAD+ and uses this information to adapt cellular energy output to cellular energy requirements. Previous studies on SIRT1 have confirmed its beneficial effects on cellular immunity to oxidative stress, reduction of fibrosis, suppression of inflammation, inhibition of apoptosis, regulation of metabolism, induction of autophagy and regulation of blood pressure. All of the above biological processes are involved in the pathogenesis of kidney diseases. Therefore, the activation of SIRT1 may become a therapeutic target to improve the clinical outcome of kidney diseases. In this review, we give an overview of SIRT1 and its molecular targets as well as SIRT1-modulated biological processes, with a particular focus on the role of SIRT1 in kidney diseases.

Introduction

Acetylation is an evolutionarily conserved posttranslational modification occurring on lysine residues. Increasing evidence has demonstrated the critical role of histone acetylation/deacetylation in gene transcription (1,2). Histone acetylation mediated by histone acetyltransferases promotes an open chromatin formation, which provides binding sites for basal transcription factors and RNA polymerase II to facilitate gene transcription. In contrast, histone deacetylases (HDACs) remove acetyl group from lysine residues of histone, resulting in chromatin compaction and transcription repression (3). In addition, emerging evidence indicates that transcription factors and transcriptional coregulatory proteins are also regulated by acetylation/deacetylation (3, 4, 5, 6). Three classes of mammalian HDACs have been identified, of which silent information regulator 2 (Sir2) or class III HDACs are NAD+-dependent HDACs using coenzyme NAD+ for the removal of acetyl groups from lysine residues of histone proteins and nonhistone proteins (7).

Sirtuins, a group of NAD+-dependent HDACs, are members of the Sir2 family. Mammals have several different sirtuins. Because of their different acylprotein substrate specificity, binding partners and intracellular localization, sirtuins are divided into sirtuin 1–7 (SIRT1–7) (8). SIRT1 and SIRT2 can be found in both the cytoplasm and the nucleus. SIRT6 and SIRT7 are almost exclusively in the nucleus, but at different subnuclear localizations. SIRT3 to SIRT5 are located in the mitochondria (9). The most studied mammalian sirtuin is SIRT1, which is identified as an important molecule necessary for caloric restriction-related longevity. Upon calorie restriction, increased intracellular NAD+ concentrations promote SIRT1 activity. By using the coenzyme NAD+, SIRT1 promotes chromatin silencing and transcriptional repression through deacetylation of histones (10). Furthermore, histone methylation and acetylation are often coordinately regulated. Histone deacetylation by SIRT1 may also enhance histone methylation (11,12). Histone methylation could activate or repress gene expression, depending on the methylation sites (13). For example, methylation at H3K9, H4K20 and H3K27 represses gene expression, whereas methylation at H3K4, H3K36, and H3K79 results in chromatin activation in transcriptional controls (14). In addition, several transcription factors and transcriptional coregulatory proteins, such as p53 and nuclear factor-κB (NF-κB), also serve as substrates for SIRT1 (15,16). Acetylation of transcription factors and transcriptional coregulatory proteins has been demonstrated to modulate their functions by altering their stability, activity, subcellular localization, DNA-binding ability and protein-protein interactions (17,18). It is noteworthy that, depending on the protein and acetylation site, deacetylation may exert divergent, or even opposite, effects. For example, deacetylation of p53 reduced its DNA-binding ability (15). However, deacetylation caused enhanced DNA-binding ability of forkhead box O1 (FOXO1) (19). Through deacetylation of histones and transcriptional regulators, SIRT1 regulates transcriptional activity and is therefore linked to cellular energy metabolism, fibrosis, mitochondrial biogenesis, stress responses, apoptosis, inflammation and autophagy. Consistent with its dual cellular localization, SIRT1 targets can be found in both the nucleus and the cytoplasm. SIRT1 activation exerts protective effects on multiple organs upon oxidative stress, including kidney (12,20, 21, 22, 23), whereas SIRT1 knockout (KO) mice show aggravation of renal changes occurring in diabetes and acute kidney injury (12,24).

SIRT1 Actions

SIRT1 Preserves Podocyte Function by Targeting Claudin-1

Diabetic nephropathy (DN) is one of the microvascular complications of diabetes. One of the earliest features in DN is the loss of podocytes, also known as glomerular epithelial cells (25). The glomerular filtration barrier consists of three parts: endothelial cells, the glomerular basement membrane and podocytes. Podocytes have a prominent role in albumin handling and maintaining the integrity of the glomerular filter, and podocyte injury leads to progressive proteinuric kidney diseases. Through mitochondrial and NADPH oxidase pathways, high blood glucose stimulates the generation of reactive oxygen species and leads to activation of proapoptotic p38 mitogen-activated protein kinase and caspase 3, eventually resulting in apoptosis of podocytes and proteinuria. It is generally believed that the glomerulus is the primary site of injury in DN. However, its progression correlates best with tubular epithelial degeneration and interstitial fibrosis (26,27).

Studies by Hasegawa et al. (12) showed that renal proximal tubule (PT)-specific SIRT1 could epigenetically downregulate the expression of the tight junction protein claudin-1 in podocytes and protect the glomerular changes induced by diabetes. Claudins, which are important components of tight junctions, are reported to be involved in the pathogenesis of albuminuria (28,29). Hasegawa et al. found a target for methylation, CpG islands, within the claudin-1 genes. Claudin-1 expression was regulated epigenetically through deacetylation of histone H3 and H4 by SIRT1, with subsequent CpG methylation of the claudin-1 gene by recruited DNA methyltransferase 1. For the first time, their study provided pivotal evidence for interaction between PT cells and podocytes through nicotinamide mononucleotide (NMN). Under normal conditions, high concentrations of NMN led to deacetylation of both H3 and H4 histones and enhanced CpG methylation of the claudin-1 gene by SIRT1, and eventually claudin-1 promoter was silenced in podocytes. Under diabetic conditions, PT SIRT1 expression was decreased, which decreased NMN concentrations around glomeruli. Low concentrations of NMN induced low levels of SIRT1 in podocytes, with subsequent acetylation of both H3 and H4 and hypomethylation of claudin-1 CpG regions, which led to claudin-1 overexpression in podocytes. High levels of claudin-1 in podocytes induced podocyte effacement and albuminuria (Figure 1). To confirm the above results, the investigators measured renal expression of SIRT1 and claudin-1 in human specimens with diabetes. They found that SIRT1 and claudin-1 were negatively correlated with each other. The former and the latter were negatively and positively correlated with proteinuria, respectively. Their study suggested a model in which SIRT1 in PT affected glomerular podocytes and proteinuria by maintaining NMN concentrations around glomeruli. Their study is important. On one hand, it identified SIRT1 as an important regulator of claudin-1, a key regulator of albuminuria and glomerular function. On the other hand, it suggested the SIRT1-claudin-1 crosstalk between renal tubules and glomerulus regulated renal function. The study also helps us to understand the communication among different cells in different segments of the nephron. However, more studies are needed to determine the mechanism regulating NMN concentrations in PT based on glucose condition or SIRT1 expression level. Also, their data suggest that NMN derived from PT cells is absorbed by podocytes, but how NMN goes upstream against glomerular filtration force remains unclear. Nevertheless, their exciting results encourage further investigation of SIRT1 and claudin-1 as therapeutic targets of DN. Furthermore, there was also a study suggesting that claudin-1 contributed to crescent formation in crescentic glomerulonephritis (30). Thus, future studies are needed to investigate whether SIRT1, as a negative regulator of claudin-1, can serve as a potential target to prevent or treat crescentic glomerulonephritis.
Figure 1

Renal tubule SIRT1 preserves podocyte function. Normally, SIRT1 in PT maintains glomerular NMN concentrations that lead to epigenetic silencing of claudin-1 promoter in podocytes. PT SIRT1 decreases in response to diabetes, followed by decreased glomerular NMN concentrations that in turn reduce SIRT1 expression in podocytes. Claudin-1 promoter is no longer silenced because of the downregulation of SIRT1. Consequently, high levels of claudin-1 in podocytes induce podocyte effacement and albuminuria.

SIRT1 Reduces Fibrosis by Smad3 (Targeting Mothers against Decapentaplegic Homolog 3) and Smad4

Transforming growth factor (TGF)-β is an important cytokine regulating apoptosis, cell cycle, differentiation and extracellular matrix accumulation (31, 32, 33). A large body of evidence has linked TGF-β/Smad signaling to the development and progression of renal fibrosis (34, 35, 36). Reversal of Smad3 acetylation via SIRT1 inhibited the TGF-β1-induced profibrotic response in vitro and unilateral-uretericobstruction-induced interstitial fibrosis in vivo (37, 38, 39). Furthermore, coimmunoprecipitation assay provided direct evidence of an interaction between Smad3 and SIRT1 (38,39).

In addition, the loss of SIRT1 in kidney tubular epithelial cells exacerbated injury-induced kidney fibrosis, but SIRT1 reduced epithelial-to-mesenchymal transition (EMT) in kidney fibrosis by deacetylating Smad4 and repressing the effect of TGF-β signaling on matrix metalloproteinase-7, a Smad4 target protein (40).

SIRT1 Inhibits Apoptosis by Targeting p53, Smad7, FOXO3 and FOXO4

Apoptosis removes unwanted or damaged cells and has been implicated in the pathogenesis of various kidney diseases, including DN (41, 42, 43, 44). Under diabetic conditions, oxidative stress caused by various stressors such as high glucose, angiotensin II and advanced glycation end products enhances apoptosis of glomerular mesangial cells, podocytes and renal tubular cells (44, 45, 46). Reportedly, SIRT1 deacetylates several apoptosis-related proteins, such as p53, Smad7, FOXO3 and FOXO4, protecting renal cells against damage-induced apoptosis (47, 48, 49, 50, 51).

As discussed above, loss of podocytes takes an important role in the pathogenesis of DN. In vitro study showed that high glucose-induced apoptosis in podocytes was mediated by p53 pathways (52). In vivo study showed that advanced oxidation protein products induced by diabetes led to podocyte apoptosis by a p53 apoptotic pathway, which was preceded by the increase in albuminuria (53). P53 was upregulated and activated in the renal cortex of db/db mice and streptozotocin (STZ)-induced diabetic mice and rats, leading to the increased podocyte apoptosis and albuminuria (53,54). In addition, p53 could also increase the apoptosis of mesangial cells and tubular cells, resulting in the aggravation of kidney damage (43,54,55). Furthermore, deletion of the p53 gene or inhibition of p53 protein function by its inhibitor conferred a protective phenotype because of the reduced apoptosis of renal cells (53,54). SIRT1 bound and deacetylated the C-terminal Lys382 of p53, which destabilized the p53 protein and reduced its transcriptional activity, resulting in the decrease of apoptosis (15,56,57). Resveratrol, a SIRT1 activator, was reported to ameliorate the acetylation of p53 and renal damage induced by diabetes and cisplatin (47,48). These findings suggest that the downregulation of p53 function by SIRT1 could be a possible strategy to attenuate oxidative stress-induced apoptosis of glomerular mesangial cells, podocytes and renal tubular cells. Actually, a regulatory feedback loop exists between SIRT1 and p53: SIRT1 interacts with and deacetylates p53, inhibiting its transcriptional activity; p53 can repress SIRT1 transcription through binding to two response elements within the SIRT1 promoter (58).

Studies by Kume et al. (49) have identified Smad7 as a new substrate for SIRT1. SIRT1 directly interacted with and deacetylated the lysine residues (Lys-64 and −70) of Smad7, leading to the enhanced degradation and reduced expression of Smad7 in SIRT1-overexpressing mesangial cells. Overexpression of Smad7 and stimulation by TGF-β increased mesangial cell apoptosis, but this effect was blocked by SIRT1 overexpression.

Members of FOXO are key regulators of apoptosis, lipid metabolism, cellular proliferation, inflammation, and autophagy and stress resistance (59,60). The transcriptional activity of FOXO is tightly regulated by posttranslational modification, including acetylation, phosphorylation and ubiquitination. SIRT1 could interact with and deacetylate FOXO3 (61). It is noteworthy that deacetylation of FOXO3 by SIRT1 inhibited its transcriptional activity on proapoptotic genes but drove its actions toward the induction of antioxidant and cytoprotective genes, whereas highly acetylated forms of FOXO3 favored expression of apoptosis-related genes, such as Bim, TRAIL and FasL (61). SIRT1 protected renal tubular cells against apoptosis by the bidirectional regulation of catalase expression via deacetylation of FOXO3 (50). In addition, SIRT1 reduced FOXO4 acetylation, preventing podocyte from apoptosis in diabetes (51). Actually, the study by Nemoto et al. (62) indicated SIRT1 expression to be regulated in a feed-forward loop by FOXO3a. The above observations should stimulate the investigation of SIRT1 as a therapeutic target to prevent renal cells from diabetes-induced apoptosis.

SIRT1 Suppresses Inflammation by Targeting NF-κB and High-Mobility Group Box 1 (HMGB1)

NF-κB is a ubiquitously distributed transcription factor that affects inflammation, apoptosis, adhesion, angiogenesis and cell cycle through the regulation of its target genes. It consists of homo-and heterodimers of a group of proteins, namely RelA (also called p65), c-Rel, NF-κB1 (p50 and its precursor p105), NF-κB2 (p52 and its precursor p100) and RelB (63,64). Under physiological conditions, the dimers of NF-κB are bound to IκB proteins, which mask the nuclear translocation signal of NF-κB and retain NF-κB in the cytoplasm. Because of that, NF-κB remains inactive. In response to diverse stimuli, its inhibitory proteins, namely IκB, are phosphorylated. Consequently, NF-κB is free from IκB and NF-κB translocates into nuclear to interact with promoters of target genes, thus activating the transcription of many inflammatory genes coding for cytokines and adhesion molecules.

Inflammation is one of the key mechanisms responsible for the development and progression of acute and chronic kidney diseases, including acute kidney injury and DN. Many inflammation-related proteins regulated by NF-κB, such as vascular cell adhesion protein 1, intercellular adhesion molecule 1 and monocyte chemotactic protein 1, play important roles in kidney diseases (65, 66, 67, 68, 69). Many stimuli relevant to kidney injury can activate NF-κB, such as high glucose, advanced glycosylation end products, cytokines, growth factors, toll-like receptors and proteinuria. Large amounts of experimental results have demonstrated that inhibition of NF-κB ameliorates inflammation, conferring a renoprotective phenotype (70, 71, 72, 73, 74).

Transcriptionally active NF-κB is usually composed of a heterodimeric protein complex that contains a DNA-binding component and an acidic transactivation domain (16). The most studied one is the heterodimer consisting of the p65 and p50 protein. SIRT1 binds and deacetylates Lys310 of p65 subunit, inhibiting transcriptional activity (16,75). Furthermore, SIRT1 deletion activated NF-κB because of the increased NF-κB acetylation, resulting in enhanced inflammation and aggravated acute kidney injury after lipopolysaccharide challenge (24). SIRT1 overexpression decreased cisplatin-induced acetylation of NF-κB p65 subunit and cytotoxicity in renal PT cells (76). Evidence also indicated that renal inflammation was induced by increased levels of acetylated NF-κB p65 owing to reduced SIRT1 protein expression, whereas dietary restriction exerted anti-inflammatory effects by restoring SIRT1 expression in the kidney of the diabetic Wistar fatty (fa/fa) rat (77). Actually, the study by Katto et al. (64) indicated SIRT1 expression is regulated in a positive feedback loop by NF-κB. These authors also identified the NF-κB binding sites within the SIRT1 promoter by using electrophoretic mobility shift assay. However, these results have been controversial. There were also results suggesting that NF-κB inhibited SIRT1 expression and signaling (78,79) (see Regulation by Transcription Factors below).

HMGB1, known as a nuclear factor and secreted protein (80), was also served as the target of SIRT1. HMGB1 is a 215-amino acid protein and its structure is extremely conservative (81). Under physiological conditions, HMGB1 is mainly in the nucleus, where it acts as an architectural chromatin-binding factor to stabilize nucleosomes. During stress, HMGB1 can be released from nonlethally damaged and necrotic cells into the extracellular milieu, where it activates macrophage and induces systemic inflammation via Toll-like receptor 4 and the receptor for advanced glycosylation end products (82,83). More recent study has shown that HMGB1 acetylation plays an important role in HMGB1 localization and SIRT1 deacetylated the lysine residues (Lys-55, −88, −90 and −177) of HMGB1 (84). Deletion of SIRT1 increased HMGB1 acetylation and reduced nuclear HMGB1, resulting in enhanced HMGB1 release into circulation and increased renal damage. Resveratrol, known as the SIRT1 activator, deacetylated HMGB1, leading to increased nuclear HMGB1 and reduced tubular damage during acute kidney injury (84).

SIRT1 Induces Autophagy by Targeting Autophagy-Related Genes and FOXO3

Autophagy, a lysosomal degradation process, plays a key role in removing protein aggregates as well as damaged or excess organelles under various stress conditions. However, the function of autophagy is not only the simple elimination of cytoplasmic materials, but also serves as a dynamic recycling system that produces new building blocks and energy for cellular renovation and homeostasis (85). In nutrient excess conditions, autophagic activity is decreased, but once nutrients are depleted, autophagy is activated to provide energy resources for cells. The study of autophagy has revealed that autophagy deficiencies under nutrient excess conditions were involved in the pathogenesis of aging-related or metabolic diseases, including kidney disease (85,86). Currently, nephrologists are also entering this exciting field, and it has been revealed that autophagy has a renoprotective effect in a number of animal models including those used for acute kidney injury and aging (86, 87, 88, 89, 90, 91). More specifically, autophagy enhances cell adaptation to hypoxia and maintains podocyte homeostasis in aging mice (86,87). In addition, autophagy protects kidney from acute ischemic and ischemia-reperfusion injury as well as cisplatin-induced nephrotoxicity (89,92). SIRT1-mediated autophagy was reportedly essential in the calorie restriction-mediated protection of aged kidneys (86). SIRT1 directly deacetylated Atg5, Atg7 and Atg8 in an NAD-dependent fashion, forming a molecular complex with several components of autophagy machinery including deacetylated Atg5, Atg7 and Atg8. Consequently, autophagy was induced by SIRT1 (93). Nevertheless, autophagy was inhibited in SIRT1 KO mice during starvation, leading to the accumulation of damaged organelles, especially mitochondria, and disruption of energy homeostasis. The same phenomenon was observed in Atg5 KO mice (93). However, the substrate residues and consequences of the deacetylation remain unclear.

Under nutrient excess conditions, such as obesity and diabetes, high plasma levels of free fatty acids and high glucose levels enhance the production of reactive oxygen species. Intracellular accumulation of reactive oxygen species causes injury to the mitochondria. Thus, restoring autophagic activity and removing the damaged mitochondria under nutrient excess conditions are likely to be essential for maintaining healthy populations of functional mitochondria. However, direct evidence showing the relationship between autophagy and DN is still not clear. Podocytes, the key element of the glomerular filtration barrier, are highly differentiated and unable to proliferate. Podocyte injury or loss contributes to progressive proteinuria in DN. Podocytes exhibited high basal level of autophagy, indicating that autophagy plays an essential role in maintaining podocyte homeostasis under nonstress conditions (94). In addition, podocyte-specific deletion of Atg5 led to a glomerulopathy and accumulation of oxidized and ubiquitinated proteins, endoplasmic reticulum (ER) stress and proteinuria in aging mice (87). A recent report showed that under high glucose conditions in vitro and under diabetic conditions in vivo, high basal levels of podocyte autophagy decreased because of the failure of ER cytoprotective function in response to high glucose-induced unmitigated stress. Consequently, the defective autophagy facilitated podocyte injury (95). These results suggested that diabetes reduced autophagic activity in podocytes, which contributed to the pathogenesis of DN. Nevertheless, SIRT1 protects the kidneys against diabetes-induced kidney disease by inducing autophagy.

In addition, SIRT1-mediated FOXO3 deacetylation also promoted autophagy in mouse aged kidney, which enhanced cell adaptation to hypoxia (86). According to their study, hypoxia causes damage to the mitochondria, and it also stimulates autophagy to remove the damaged mitochondria. Hypoxia-induced autophagy was dependent on Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3 (Bnip3). Normally, Beclin 1 interacts with Bcl-2 proteins, but this interaction could be disrupted by Bnip3, liberating Beclin 1 from Bcl-2 to induce autophagy (96). Beclin 1 was positively regulated by FOXO3a in aged kidneys (86). Calorie restriction-induced SIRT1 activation deacetylated and activated FOXO3a, which promoted Bnip3-mediated autophagy in aged kidneys, attenuating hypoxia-induced mitochondrial and renal damage. Deacetylation of FOXO1 by SIRT1 increased starvation-induced autophagy in cardiac myocytes (97). Consistent with this study, treatment with the SIRT1 activator, resveratrol, significantly increased FOXO1 activity in diabetic kidney, attenuating diabetes-induced oxidative stress and fibrosis (98).

SIRT1 Regulates Blood Pressure by Targeting Endothelial Nitric Oxide Synthase and Angiotensin II Type 1 Receptors

Hypertension plays an important role in the progression of chronic kidney disease. Nitric oxide (NO), a potent vasodilator, can protect blood vessels from thrombosis and atherosclerosis (99). In the vasculature, it is mainly generated by endothelial nitric oxide synthase (eNOS). Recent studies indicated that eNOS was involved in mitochondrial biogenesis, longevity and anti-aging effects (100,101). Nevertheless, the defective eNOS due to endothelial cell dysfunction contributed to kidney disease and cardiovascular disease, including atherosclerosis, hypertension, hypertensive nephropathy and DN (102,103). Deficiency of eNOS conferred susceptibility to DN in db/db mice (104) and in STZ-induced animal models of DN on the nephropathy-resistant C57BL/6J background (105). Reportedly, eNOS also served as a substrate for SIRT1. SIRT1 interacted with and deacetylated Lys-496 and Lys-506 in the calmodulin-binding domain of eNOS, enhancing eNOS activity and promoting endothelial NO-dependent vasodilation. Inhibition of SIRT1 decreased NO bioavailability, inhibiting NO-dependent vasodilation (106). In addition, SIRT1 suppressed the expression of angiotensin II type 1 receptor (AT1R), inhibiting AT1R-induced hypertension (107). Thus, SIRT1-induced vasodilation may contribute, at least in part, to the renoprotection of SIRT1.

SIRT1 Enhances Mitochondrial Biogenesis by Targeting Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α

Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α), a transcriptional coactivator of peroxisome proliferator-activated receptor (PPAR)-γ, is a master regulator of mitochondrial biogenesis. It coactivates nuclear respiratory factor-1, which binds to the promoter of mitochondrial transcription factor A, leading to the upregulation of mitochondrial DNA replication (108). The overexpression of PGC-1α resulted in the increase in mitochondrial number, respiratory capacity and mitochondrial protein markers (109,110). What is more, the repression of PGC-1α induced mitochondrial dysfunction and EMT in renal epithelial cells (111). As a major regulator of mitochondrial biogenesis, deacetylated PGC-1α was more effective in recruiting transcription factors to induce the expression of its target genes. Reportedly, SIRT1 catalyzed PGC-1α deacetylation, enhancing its activity (112,113). Aldosterone reduced PGC-1α expression through increasing its acetylation, leading to mitochondrial dysfunction, EMT and podocyte damage. Both overexpression of SIRT1 and resveratrol, the SIRT1 activator, restored aldosterone-induced mitochondrial dysfunction, EMT and podocyte injury through upregulation of PGC-1α expression (111,114). SRT1720, another SIRT1 activator, rescued mitochondrial function after oxidant-induced renal PT cell injury. This effect depended on SIRT1 deacetylase activity, correlated with deacetylated PGC-1α (115).

SIRT1 Modulates Hypoxic Responses by Targeting Hypoxia-Inducible Factor-1α (HIF-1α) and HIF-2α

HIF-1 and HIF-2 are oxygen-sensitive transcription factors that facilitate oxygen delivery and cellular adaptation to hypoxia. Even so, they have distinct functions and only partially overlap. HIF-1 is the main regulator of glycolytic genes (116), but hypoxic vascular endothelial growth factor and erythropoietin (EPO) induction is predominantly regulated by HIF-2 (117,118). HIFs consist of an oxygen-sensitive α-subunit and a constitutively expressed β-subunit (119). Normally, HIF-1α is expressed in most cell types of fully developed kidney, whereas HIF-2α is mainly located in renal endothelial cells and interstitial fibroblast-like cells. The activity and stability of HIF-1 predominantly depend on HIF-1α. Under conditions of normal PO2, SIRT1 reportedly inactivated HIF-1 by deacetylation of HIF-1α at Lys-674 and consequently repressed HIF-1 target genes (120). In response to hypoxia, SIRT1 activity decreased due to the reduced NAD+ levels, which allowed the acetylation and activation of HIF-1α (120). Thus, their results proposed a model whereby the NAD+-dependent regulation of SIRT1 ensured the normoxic inactivation and the hypoxic activation of HIF-1α. However, studies by Dioum et al. (121) showed that SIRT1 positively regulated HIF-2 signaling by deacetylating HIF-2α at Lys-741, leading to the increased EPO levels. It seems that the roles of SIRT1 in HIF-1α and HIF-2α functions are controversial. Further study in vitro showed that SIRT1 inhibited HIF-1α activity constantly in 10 cell lines, but regulated HIF-2α activity cell type-dependently. Knockdown of the SIRT1 gene inhibited HIF-2α activity in three cell lines, but activated that in seven cell lines. In HEK293T (human embryonic kidney) cell lines, SIRT1 inactivated HIF-1α but activated HIF-2α (122). However, whether SIRT1 could protect the kidney from hypoxia-induced damage or serve as a therapeutic target for renal anemia treatment by deacetylating HIFs remains unknown.

SIRT1 Regulates Metabolism by Targeting Sterol Regulatory Element-Binding Protein, Liver X Receptor, Nuclear Bile Acid Receptor and Insulin Receptor Substrate-2

SIRT1 regulates lipid homeostasis through the regulation of sterol regulatory element-binding protein (SREBP), liver X receptor (LXR) and nuclear bile acid receptor (FXR). SIRT1 directly deacetylates SREBP, inhibiting SREBP target gene expression and reducing lipid and cholesterol levels (123). LXRs function as cholesterol sensors to enhance reverse cholesterol transport, a process by which cholesterol is excreted into bile. SIRT1 positively regulated LXR by deacetylation at Lys-432 (124), resulting in the homeostasis of cholesterol and triglycerides. FXR is a critical regulator of lipid metabolism. Acetylation of FXR enhanced its stability but inhibited its transactivation activity. SIRT1 directly interacted with and deacetylated FXR at Lys-217, increasing its transactivation activity and resulting in ameliorative metabolic outcomes (125). Therefore, SIRT1 modulated lipid metabolism and prevented the progression of kidney diseases related to lipid metabolism disorders. SIRT1 is also involved in insulin signaling pathway. The deacetylation of insulin receptor substrate (IRS)-2 by SIRT1 was critical in insulin-induced IRS-2 tyrosine phosphorylation, which was a vital step in the insulin signaling pathway (126). It may imply the novel role of SIRT1 in the regulation of diabetes and its complications including DN.

Role of SIRT1 in Obstructive Nephropathy

Although SIRT1 has been reported to exert beneficial effects in kidney diseases through multiple pathways, emerging evidence shows that blocking SIRT1 attenuated renal interstitial fibrosis in obstructive nephropathy (127). According to this study, the SIRT1 inhibition-mediated anti-fibrotic effects were associated with dephosphorylation of platelet-derived growth factor receptor-β (PDGFRβ), epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3. However, how SIRT1 inhibition reduces EGFR and PDGFRβ phosphorylation remains unclear. Apparently, these results were in stark contrast to previous studies that SIRT1 activators attenuated renal fibrosis. Thus, the role of SIRT1 in renal fibrosis and obstructive nephropathy need further investigation.

Regulation of SIRT1 Function and Expression

Numerous studies have showed that SIRT1 deacetylates a wide range of substrates, indicating SIRT1 is in a broad spectrum of biological processes. Therefore, the molecular circuits regulating SIRT1 levels (Figure 2) may provide a new method to accumulate the therapeutic benefit of SIRT1.
Figure 2

Regulatory mechanisms of SIRT1 function and expression. Open image in new window , Stimulation; Open image in new window , inhibition; Open image in new window , tentative stimulation; Open image in new window , tentative inhibition.

Regulation Through NAD+

The catalytic activity of SIRT1 depends on the availability of cellular NAD+. Although NAD+ has many functions, it is best known for its role in redox reactions and energy metabolism. Therefore, SIRT1 activity is intrinsically linked to the energy status of the cell. Changes in energy status and the NAD+:NADH ratio could influence the activity of SIRT1. In energy excess conditions such as high-fat diets, SIRT1 activity decreased because of the decreased NAD+:NADH ratio (128,129), whereas a low-energy status such as fasting, calorie restriction, nutrient deprivation and exercise could increase SIRT1 activity by increasing the NAD+:NADH ratio (130, 131, 132). The levels of NAD+ not only affected the activity of SIRT1 but also co-ordinately altered SIRT1 expression levels (133,134).

Regulation by Transcription Factors

Numerous transcription factors can regulate the expression of SIRT1. In response to calorie restriction, cyclic AMP response-element-binding protein (CREB) induced SIRT1 expression by binding to the SIRT1 gene promoter, whereas the carbohydrate response-element-binding protein (ChREBP) repressed SIRT1 expression by binding to the ChREBP response element within the promoter of the SIRT1 gene in a high-energy state (134).

Members of the FOXO family can also mediate changes in the expression of SIRT1. FOXO1 increased SIRT1 expression by binding to the FOXO1 response elements located in the SIRT1 gene promoter (19,62). Interestingly, SIRT1 was reported to deacetylate FOXO1 and increase its transcriptional activity, suggesting the existence of a positive feedback loop between SIRT1 and FOXO1 (19). By contrast, FOXO3a-induced SIRT1 expression was mediated by the interaction with p53. FOXO3a translocated into the nucleus and formed a complex with p53 at the p53-binding sites within the SIRT1 gene promoter, thereby reducing the inhibitory effects of p53 on SIRT1 gene expression (62). FOXO3a also served as a target of the SIRT1 deacetylase activity. Unlike FOXO1, SIRT1 can either activate or repress the transcriptional activity of FOXO3a, depending on target genes and environmental stimuli (61,135).

The tumor suppressor p53, which is also a stress-responsive transcription factor, has been shown to affect SIRT1 gene expression. P53 repressed SIRT1 expression through binding to the p53-binding sites present in the SIRT1 gene promoter (62), leading to the expression of pro-apoptotic genes. Interestingly, SIRT1 was capable of deacetylating all major p53 acetylation sites and reducing its transcriptional activity (58), suggesting a negative feedback loop between SIRT1 and p53. SIRT1-dependent deacetylation of p53 suppressed apoptosis in response to oxidative stress and DNA damage (56). The antagonistic crosstalk between SIRT1 and p53 is crucial for cell homeostasis.

A number of putative binding sites for NF-κB were found within the promoter sequences of the SIRT1 gene (64,136). However, the role of NF-κB in the regulation of SIRT1 function and expression has been controversial. There was study demonstrating that the p65/RelA subunit of NF-κB-mediated tumor necrosis factor-α-induced upregulation of SIRT1 (137). Another study showed that the SIRT1 gene promoter was activated by overexpression of different NF-κB subunits, followed by enhanced expression of SIRT1 mRNA levels (64). These results implied that NF-κB could induce SIRT1 expression. On the contrary, there was also evidence indicating that NF-κB inhibited SIRT1 expression and signaling. Reportedly, NF-κB could increase the expression of microRNA-34a (miR-34a), which targeted the 3′UTR of SIRT1 and inhibited SIRT1 expression (138, 139, 140, 141). SIRT1 even became cleaved in inflammatory status (78,79). In addition, as a target of SIRT1, p65 subunit of NF-κB could be deacetylated and inactivated by SIRT1 (16).

PPARs that function as transcription factors could also regulate SIRT1 expression. PPARα induced SIRT1 expression, presumably by binding to the PPAR responsive element within the SIRT1 gene promoter (133). Interestingly, although there was no evidence that PPARα was a deacetylation target of SIRT1, SIRT1 increased PPARα activity through its coactivators, indicating a positive feedback loop between SIRT1 and PPARα (142). PPARβ/σ could also enhance SIRT1 expression through Sp1 (143). On the contrary, PPARγ reduced SIRT1 expression, possibly by interacting with the promoter of the SIRT1 gene (144). Unlike PPARα and PPARβ/σ, PPARγ was a deacetylation target of SIRT1 and was repressed by SIRT1, suggesting a negative feedback loop between SIRT1 and PPARγ (144).

Regulation by AMP-Activated Protein Kinase

AMP-activated protein kinase (AMPK), known as a fuel-sensing enzyme, could increase NAD+ availability that would favor SIRT1 function and expression (145). The alternative mechanisms by which AMPK can stimulate SIRT1 activity were also reported recently. For instance, AMPK could directly phosphorylate SIRT1, resulting in the dissociation of SIRT1 and its negative regulator (146). There were also studies showing that SIRT1 acted upstream of AMPK. Overexpression of SIRT1 stimulated the AMPK phosphorylation (147), whereas shRNA-mediated SIRT1 knockdown reduced AMPK phosphorylation (148). However, these results might need further confirmation because other studies showed that the loss of SIRT1 was associated with increased AMPK (149).

Regulation by microRNAs

SIRT1 expression is also under the control of several miRNAs, including miR-34a and miR-195. These miRNAs bound SIRT1 mRNAs and reduced their stability or suppressed their translation; consequently, SIRT1 expression was decreased (140,150).

Regulation by Small Chemicals

SIRT1 can be activated or inhibited by small chemicals. As discussed above, SIRT1 activators could protect the kidneys via modulation of target genes and proteins. SIRT1 inhibitors could induce acetylation and activation of p53, making them promising compounds for the treatment of cancer. Resveratrol and sirtinol have been extensively investigated and have been widely referred to as the SIRT1 activator and inhibitor, respectively (151,152). More recently, the synthetic SIRT1 activators with improved bioavailability and sirtinol analogs with improved potency have been developed (153,154).

Conclusion

Accumulated evidence has demonstrated the beneficial effects of SIRT1 on (a) suppression of apoptosis, inflammation and fibrosis; (b) induction of autophagy and EPO expression; and (c) regulation of lipid metabolism, glucose homeostasis and blood pressure (Figure 3). Importantly, emerging evidence suggests that SIRT1 can protect the kidneys against DN and reduce albuminuria via modulation of the expression of the tight junction protein claudin-1 in podocytes (12). In this review, we provide an overview of SIRT1-modulated biological processes related to kidney diseases and discuss how SIRT1 protects the kidneys via modulation of target genes and proteins. The general effect of SIRT1 is renoprotection; however, further studies are still needed to develop economical and effective SIRT1 activators and to determine whether these new activators or inhibitors can improve the clinical outcome of kidney diseases.
Figure 3

The role of SIRT1 in the kidney. SIRT1 exerts renoprotective effects by preserving podocyte function, reducing fibrosis, inhibiting apoptosis, suppressing inflammation, inducing autophagy and EPO expression, regulating blood pressure and enhancing mitochondrial biogenesis through deaceylation of promoter-bound histones and several target proteins. →, Stimulation;?, inhibition. Furthermore, SIRT1 protects the kidneys from renal diseases derived from diabetes and lipid metabolism disorders by deaceylation of IRS-2, SREBP LXR and FXR. In addition, although study also showed that blocking SIRT1 attenuated renal interstitial fibrosis in obstructive nephropathy, the direct targets related to these effects remain unknown (see the detailed discussion in the text). Atgs, autophagy-related genes.

Disclosure

The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.

Notes

Acknowledgments

The citations from the authors group were supported in part by the National Science Foundation of China (81170669 to L Miao) and the National Institutes of Health (1R01DK 091338-01A1 to L Cai). We would like to thank Amy Y Cai for assistance in making the figures for this manuscript. We would also like to express our gratitude to all the scientists participating in this work.

References

  1. 1.
    Bahari-Javan S, Sananbenesi F, Fischer A. (2014) Histone-acetylation: a link between Alzheimer’s disease and post-traumatic stress disorder? Front. Neurosci. 8:160.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Bassett SA, Barnett MP. (2014) The role of dietary histone deacetylases (HDACs) inhibitors in health and disease. Nutrients. 6:4273–301.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Yuan H, et al. (2013) Involvement of p300/CBP and epigenetic histone acetylation in TGF-beta1-mediated gene transcription in mesangial cells. Am. J. Physiol. Renal. Physiol. 304:F601–13.PubMedCrossRefGoogle Scholar
  4. 4.
    Li Y, et al. (2014) Novel role of silent information regulator 1 in acute endothelial cell oxidative stress injury. Biochim. Biophys. Acta. 1842:2246–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Bugyei-Twum A, et al. (2014) High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc. Diabetol 13:89.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Hwang YJ, Song J, Kim HR, Hwang KA. (2014) Oleanolic acid regulates NF-κB signaling by suppressing MafK expression in RAW 264.7 cells. BMB Rep. 47:524–9.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Lee HB, Noh H, Seo JY, Yu MR, Ha H. (2007) Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney Int. S61–6.CrossRefGoogle Scholar
  8. 8.
    Kume S, Thomas MC, Koya D. (2012) Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes. 61:23–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell. 16:4623–35.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Xie J, Zhang X, Zhang L. (2013) Negative regulation of inflammation by SIRT1. Pharmacol. Res. 67:60–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Fuks F. (2005) DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 15:490–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Hasegawa K, et al. (2013) Renal tubular SIRT1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat. Med. 19:1496–504.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Rea S, et al. (2000) Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 406:593–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Martin C, Zhang Y. (2005) The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell. Biol. 6:838–49.PubMedCrossRefGoogle Scholar
  15. 15.
    Vaziri H, et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 107:149–59.PubMedCrossRefGoogle Scholar
  16. 16.
    Yeung F, et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:2369–80.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Sadoul K, Boyault C, Pabion M, Khochbin S. (2008) Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie. 90:306–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Wang C, Tian L, Popov VM, Pestell RG. (2011) Acetylation and nuclear receptor action. J. Steroid. Biochem. Mol. Biol. 123:91–100.PubMedCrossRefGoogle Scholar
  19. 19.
    Xiong S, Salazar G, Patrushev N, Alexander RW. (2011) FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J. Biol. Chem. 286:5289–99.PubMedCrossRefGoogle Scholar
  20. 20.
    Xu F, et al. (2014) Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-kappaB pathway. Int. J. Endocrinol. 2014:289327.Google Scholar
  21. 21.
    Wen D, et al. (2013) Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One.8:e82336.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Elbe H, et al. (2015) Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Hum. Exp. Toxicol. 34:100–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Huang K, et al. (2013) SIRT1 resists advanced glycation end products-induced expressions of fibronectin and TGF-beta1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic. Biol. Med. 65:528–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Gao R, et al. (2014) SIRT1 deletion leads to enhanced inflammation and aggravates endotoxin-induced acute kidney injury. PLoS One. 9:e98909.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Susztak K, Raff AC, Schiffer M, Bottinger EP. (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 55:225–33.PubMedCrossRefGoogle Scholar
  26. 26.
    Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP. (2005) Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2:e45.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Bonventre JV. (2012) Can we target tubular damage to prevent renal function decline in diabetes? Semin. Nephrol. 32:452–62.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Ohse T, et al. (2010) De novo expression of podocyte proteins in parietal epithelial cells during experimental glomerular disease. Am. J. Physiol. Renal Physiol. 298:F702–11.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhang J, et al. (2012) De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am. J. Physiol. Renal Physiol. 302:F571–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Koda R, et al. (2014) Expression of tight junction protein claudin-1 in human crescentic glomerulonephritis. Int. J. Nephrol. 2014:598670.Google Scholar
  31. 31.
    Kim D, et al. (2014) Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor alpha-mediated transforming growth factor-beta1/Smad signaling pathway. Nephrol. Dial. Transplant. 29:2043–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Wei J, et al. (2013) Knockdown of thioredoxin-interacting protein ameliorates high glucose-induced epithelial to mesenchymal transition in renal tubular epithelial cells. Cell Signal. 25:2788–96.PubMedCrossRefGoogle Scholar
  33. 33.
    Das R, et al. (2014) Upregulation of mitochondrial Nox4 mediates TGF-beta-induced apoptosis in cultured mouse podocytes. Am. J. Physiol. Renal Physiol. 306:F155–67.PubMedCrossRefGoogle Scholar
  34. 34.
    Samarakoon R, et al. (2013) Induction of renal fibrotic genes by TGF-beta1 requires EGFR activation, p53 and reactive oxygen species. Cell Signal. 25:2198–209.PubMedCrossRefGoogle Scholar
  35. 35.
    Yao Q, et al. (2008) The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions. Nephron Exp. Nephrol. 109:e71–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Koutroutsos K, et al. (2014) Effect of Smad pathway activation on podocyte cell cycle regulation: an immunohistochemical evaluation. Ren. Fail. 36:1310–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Liang J, Tian S, Han J, Xiong P. (2014) Resveratrol as a therapeutic agent for renal fibrosis induced by unilateral ureteral obstruction. Ren. Fail. 36:285–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Li J, Qu X, Ricardo SD, Bertram JF, Nikolic-Paterson DJ. (2010) Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am. J. Pathol. 177:1065–71.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Huang XZ, et al. (2014) SIRT1 activation ameliorates renal fibrosis by inhibiting the TGF-beta/Smad3 pathway. J. Cell. Biochem. 115:996–1005.PubMedCrossRefGoogle Scholar
  40. 40.
    Simic P, et al. (2013) SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 3:1175–86.PubMedCrossRefGoogle Scholar
  41. 41.
    Jung DS, et al. (2012) Apoptosis occurs differentially according to glomerular size in diabetic kidney disease. Nephrology Dialysis Transplantation. 27:259–66.CrossRefGoogle Scholar
  42. 42.
    Chen Y, et al. (2014) Down-regulation of PERK-ATF4-CHOP pathway by astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats. Cell Physiol. Biochem. 3:1975–87.CrossRefGoogle Scholar
  43. 43.
    Peng J, et al. (2015) Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int. 87:137–50.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Wang W, et al. (2015) TRB3 mediates renal tubular cell apoptosis associated with proteinuria. Clin. Exp. Med. 15:167–77.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Kim D, et al. (2014) Ubiquitination-dependent CARM1 degradation facilitates Notch1-mediated podocyte apoptosis in diabetic nephropathy. Cell Signal. 26:1774–82.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Meek RL, et al. (2013) Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrol. Dial. Transplant. 28:1711–20.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kim DH, et al. (2011) SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53. Am. J. Physiol. Renal Physiol. 301:F427–35.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. (2008) Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic. Res. 42:397–404.PubMedCrossRefGoogle Scholar
  49. 49.
    Kume S, et al. (2007) SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J. Biol. Chem. 282:151–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Hasegawa K, et al. (2008) SIRT1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem. Biophys. Res. Commun. 372:51–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Chuang PY, et al. (20110 Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One. 6:e23566.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Gao F, et al. (2013) Notch pathway is involved in high glucose-induced apoptosis in podocytes via Bcl-2 and p53 pathways. J. Cell. Biochem. 114:1029–38.PubMedCrossRefGoogle Scholar
  53. 53.
    Menini S, et al. (2007) Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia. 50:2591–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Deshpande SD, et al. (2013) Transforming growth factor-beta-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 62:3151–62.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Han SY, et al. (2006) Apoptosis by cyclosporine in mesangial cells. Trans-plant. Proc. 38:2244–6.CrossRefGoogle Scholar
  56. 56.
    Luo J, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:137–48.PubMedCrossRefGoogle Scholar
  57. 57.
    Langley E, et al. (2002) Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21:2383–96.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Brooks CL, Gu W. (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer. 9:123–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Gross DN, van den Heuvel AP, Birnbaum MJ. (2008) The role of FoxO in the regulation of metabolism. Oncogene. 27:2320–36.PubMedCrossRefGoogle Scholar
  60. 60.
    Wang Y, Zhou Y, Graves DT. (2014) FOXO transcription factors: their clinical significance and regulation. Biomed. Res. Int. 2014:925350.Google Scholar
  61. 61.
    Brunet A, et al. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 303:2011–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Nemoto S, Fergusson MM, Finkel T. (2004) Nutrient availability regulates SIRT1 through a fork-head-dependent pathway. Science. 306:2105–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Pedruzzi LM, Stockler-Pinto MB, Leite M Jr, Mafra D. (2012) Nrf2-keap1 system versus NF-kappaB: the good and the evil in chronic kidney disease? Biochimie. 94:2461–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Katto J, Engel N, Abbas W, Herbein G, Mahlknecht U. (2013) Transcription factor NFkappaB regulates the expression of the histone deacetylase SIRT1. Clin. Epigenetics. 5:11.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Hayden MS, Ghosh S. (2008) Shared principles in NF-kappaB signaling. Cell. 132:344–62.PubMedCrossRefGoogle Scholar
  66. 66.
    Lee HJ, et al. (2014) Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model. Am. J. Nephrol. 40:56–63.PubMedCrossRefGoogle Scholar
  67. 67.
    Roy MS, Janal MN, Crosby J, Donnelly R. (2015) Markers of endothelial dysfunction and inflammation predict progression of diabetic nephropathy in African Americans with type 1 diabetes. Kidney Int. 87:427–33.PubMedCrossRefGoogle Scholar
  68. 68.
    Jialal I, Major AM, Devaraj S. (2014) Global tolllike receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy. J. Diabetes Complications. 28:755–61.PubMedCrossRefGoogle Scholar
  69. 69.
    Wu H, et al. (2014) The role of MicroRNAs in diabetic nephropathy. J. Diabetes Res. 2014:920134.Google Scholar
  70. 70.
    Shimo T, et al. (2013) A novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice. Am. J. Nephrol. 37:302–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Xie X, et al. (2012) Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-kappaB signaling pathway in rat glomerular mesangial cells. Mol. Cell. Endocrinol. 362:183–93.PubMedCrossRefGoogle Scholar
  72. 72.
    Wu X, et al. (2012) Tanshinone IIA prevents uric acid nephropathy in rats through NF-kappaB inhibition. Planta. Med. 78:866–73.PubMedCrossRefGoogle Scholar
  73. 73.
    Machado RA, et al. (2012) Sodium butyrate decreases the activation of NF-kappaB reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. Nephrol. Dial. Transplant. 27:3136–40.PubMedCrossRefGoogle Scholar
  74. 74.
    Du S, et al. (2009) Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J. Immunol. 182:7201–11.PubMedCrossRefGoogle Scholar
  75. 75.
    Salminen A, Kauppinen A, Suuronen T, Kaarniranta K. (2008) SIRT1 longevity factor suppresses NF-kappaB -driven immune responses: regulation of aging via NF-kappaB acetylation? Bioessays. 30:939–42.PubMedCrossRefGoogle Scholar
  76. 76.
    Jung YJ, et al. (2012) SIRT1 overexpression decreases cisplatin-induced acetylation of NF-kappaB p65 subunit and cytotoxicity in renal proximal tubule cells. Biochem. Biophys. Res. Commun. 419:206–10.PubMedCrossRefGoogle Scholar
  77. 77.
    Kitada M, Takeda A, Nagai T, Ito H, Kanasaki K, Koya D. (2011) Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of SIRT1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp. Diabetes Res. 2011:908185.Google Scholar
  78. 78.
    Dvir-Ginzberg M, et al. (2011) Tumor necrosis factor alpha-mediated cleavage and inactivation of SIRT1 in human osteoarthritic chondrocytes. Arthritis Rheum. 63:2363–73.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Chalkiadaki A, Guarente L. (2012) High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab. 16:180–8.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Czura CJ, Wang H, Tracey KJ. (2001) Dual roles for HMGB1: DNA binding and cytokine. J. Endotoxin Res. 7:315–21.PubMedCrossRefGoogle Scholar
  81. 81.
    Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. (2002) HMGB1 as a DNA-binding cytokine. J. Leukoc. Biol. 72:1084–91.PubMedGoogle Scholar
  82. 82.
    Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Karuppagounder V, et al. (2014) Resveratrol attenuates HMGB1 signaling and inflammation in house dust mite-induced atopic dermatitis in mice. Int. Immunopharmacol. 23:617–23.PubMedCrossRefGoogle Scholar
  84. 84.
    Rabadi MM, et al. (2015) High-mobility group box 1 is a novel deacetylation target of Sirtuin1. Kidney Int. 87:95–108.PubMedCrossRefGoogle Scholar
  85. 85.
    Mizushima N, Komatsu M. (2011) Autophagy: renovation of cells and tissues. Cell. 147:728–41.PubMedCrossRefGoogle Scholar
  86. 86.
    Kume S, et al. (2010) Calorie restriction enhances cell adaptation to hypoxia through SIRT1-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest. 120:1043–55.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Hartleben B, et al. (2010) Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120:1084–96.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Jiang M, Liu K, Luo J, Dong Z. (2010) Autophagy is a renoprotective mechanism during in vitro hypoxia and in vivo ischemia-reperfusion injury. Am. J. Pathol. 176:1181–92.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Kimura T, et al. (2011) Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J. Am. Soc. Nephrol. 22:902–13.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Periyasamy-Thandavan S, et al. (2008) Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int. 74:631–40.PubMedCrossRefGoogle Scholar
  91. 91.
    Inoue K, et al. (2010) Cisplatin-induced macroautophagy occurs prior to apoptosis in proximal tubules in vivo. Clin. Exp. Nephrol. 14:112–22.PubMedCrossRefGoogle Scholar
  92. 92.
    Kaushal GP. (2012) Autophagy protects proximal tubular cells from injury and apoptosis. Kidney Int. 82:1250–3.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Lee IH, et al. (2008) A role for the NAD-dependent deacetylase SIRT1 in the regulation of autophagy. Proc. Natl. Acad. Sci. U. S. A. 105:3374–9.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Yamahara K, et al. (2013) The role of autophagy in the pathogenesis of diabetic nephropathy. J. Diabetes Res. 2013:193757.Google Scholar
  95. 95.
    Fang L, et al. (2013) Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One. 8:e60546.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Bellot G, et al. (2009) Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 29:2570–81.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Hariharan N, et al. (2010) Deacetylation of FoxO by SIRT1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes. Circ. Res. 107:1470–82.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Wu L, Zhang Y, Ma X, Zhang N, Qin G. (2012) The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 39:9085–93.PubMedCrossRefGoogle Scholar
  99. 99.
    Xia N, et al. (2013) Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide. 32:29–35.PubMedCrossRefGoogle Scholar
  100. 100.
    Csiszar A, et al. (2009) Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 297:H13–20.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Nisoli E, et al. (2005) Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science. 310:314–7.PubMedCrossRefGoogle Scholar
  102. 102.
    Yu W, Fu YC, Chen CJ, Wang X, Wang W. (2009) SIRT1: a novel target to prevent atherosclerosis. J. Cell. Biochem. 108:10–3.PubMedCrossRefGoogle Scholar
  103. 103.
    Nakagawa T, et al. (2011) Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat. Rev. Nephrol. 7:36–44.PubMedCrossRefGoogle Scholar
  104. 104.
    Zhao HJ, et al. (2006) Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J. Am. Soc. Nephrol. 17:2664–9.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Nakagawa T, et al. (2007) Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J. Am. Soc. Nephrol. 18:539–50.PubMedCrossRefGoogle Scholar
  106. 106.
    Mattagajasingh I, et al. (2007) SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 104:14855–60.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Miyazaki R, et al. (2008) SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 28:1263–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Wu Z, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell. 98:115–24.PubMedCrossRefGoogle Scholar
  109. 109.
    Rasbach KA, Schnellmann RG. (2007) Signaling of mitochondrial biogenesis following oxidant injury. J. Biol. Chem. 282:2355–62.PubMedCrossRefGoogle Scholar
  110. 110.
    Lehman JJ, et al. (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 106:847–56.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Yuan Y, et al. (2012) Mitochondrial dysfunction accounts for aldosterone-induced epithelial-to-mesenchymal transition of renal proximal tubular epithelial cells. Free Radic. Biol. Med. 53:30–43.PubMedCrossRefGoogle Scholar
  112. 112.
    Nemoto S, Fergusson MM, Finkel T. (2005) SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J. Biol. Chem. 280:16456–60.PubMedCrossRefGoogle Scholar
  113. 113.
    Rodgers JT, et al. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 434:113–8.PubMedCrossRefGoogle Scholar
  114. 114.
    Yuan Y, et al. (2012) Activation of peroxisome proliferator-activated receptor-gamma coactivator 1alpha ameliorates mitochondrial dysfunction and protects podocytes from aldosterone-induced injury. Kidney Int. 82:771–89.PubMedCrossRefGoogle Scholar
  115. 115.
    Funk JA, Odejinmi S, Schnellmann RG. (2010) SRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333:593–601.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23:9361–74.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Morita M, et al. (2003) HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J. 22:1134–46.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Warnecke C, et al. (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 18:1462–4.PubMedCrossRefGoogle Scholar
  119. 119.
    Haase VH. (2006) Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal Physiol. 291:F271–81.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. (2010) Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol. Cell. 38:864–78.PubMedCrossRefGoogle Scholar
  121. 121.
    Dioum EM, et al. (2009) Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 324:1289–93.PubMedCrossRefGoogle Scholar
  122. 122.
    Yoon H, Shin SH, Shin DH, Chun YS, Park JW. (2014) Differential roles of SIRT1 in HIF-1alpha and HIF-2alpha mediated hypoxic responses. Biochem. Biophys. Res. Commun. 444:36–43.PubMedCrossRefGoogle Scholar
  123. 123.
    Walker AK, et al. (2010) Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24:1403–17.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Li X, et al. (2007) SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell. 28:91–106.PubMedCrossRefGoogle Scholar
  125. 125.
    Kemper JK, et al. (2009) FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 10:392–404.PubMedPubMedCentralCrossRefGoogle Scholar
  126. 126.
    Zhang J. (2007) The direct involvement of SIRT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J. Biol. Chem. 282:34356–64.PubMedCrossRefGoogle Scholar
  127. 127.
    Ponnusamy M, et al. (2014) Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J. Pharmacol. Exp. Ther. 350:243–56.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Yoshino J, Mills KF, Yoon MJ, Imai S. (2011) Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14:528–36.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Bao L, et al. (2014) Grape seed proanthocyanidin extracts ameliorate podocyte injury by activating peroxisome proliferator-activated receptor-gamma coactivator 1alpha in low-dose streptozotocin-and high-carbohydrate/high-fat diet-induced diabetic rats. Food Funct. 5:1872–80.PubMedCrossRefGoogle Scholar
  130. 130.
    Chen D, et al. (2008) Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22:1753–7.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Lai CH, et al. (2014) Exercise training enhanced SIRT1 longevity signaling replaces the IGF1 survival pathway to attenuate aging-induced rat heart apoptosis. Age (Dordr). 36:9706.CrossRefGoogle Scholar
  132. 132.
    Tikoo K, Lodea S, Karpe PA, Kumar S. (2014) Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy. Biochem. Biophys. Res. Commun. 450:1581–6.PubMedCrossRefGoogle Scholar
  133. 133.
    Hayashida S, et al. (2010) Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Mol. Cell Biochem. 339:285–92.PubMedCrossRefGoogle Scholar
  134. 134.
    Noriega LG, et al. (2011) CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep. 12:1069–76.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Motta MC, et al. (2004) Mammalian SIRT1 represses forkhead transcription factors. Cell. 116:551–63.PubMedCrossRefGoogle Scholar
  136. 136.
    Voelter-Mahlknecht S, Mahlknecht U. (2006) Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int. J. Mol. Med. 17:59–67.PubMedGoogle Scholar
  137. 137.
    Zhang HN, et al. (2010) Involvement of the p65/RelA subunit of NF-kappaB in TNF-alpha-induced SIRT1 expression in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 397:569–75.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    Zhao Y, et al. (2013) Regulation of TREM2 expression by an NF-small ka, CyrillicB-sensitive miRNA-34a. Neuroreport. 24:318–23.PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Forte E, et al. (2012) The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. J. Virol. 86:6889–98.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Yamakuchi M, Ferlito M, Lowenstein CJ. (2008) miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 105:13421–6.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Li J, et al. (2012) Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells. BMC Mol. Biol. 13:4.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Purushotham A, et al. (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:327–38.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Okazaki M, et al. (2010) PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocr. J. 57:403–13.PubMedCrossRefGoogle Scholar
  144. 144.
    Han L, et al. (2010) SIRT1 is regulated by a PPARγ-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res. 38:7458–71.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Canto C, et al. (2009) AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. 458:1056–60.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Nin V, et al. (2012) Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J. Biol. Chem. 287:23489–501.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Hou X, et al. (2008) SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283:20015–26.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Lan F, Cacicedo JM, Ruderman N, Ido Y. (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1: possible role in AMP-activated protein kinase activation. J. Biol. Chem. 283:27628–35.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Narala SR, et al. (2008) SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol. Biol. Cell. 19:1210–9.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Zhu H, et al. (2011) MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating SIRT1. Cardiovasc. Res. 92:75–84.PubMedCrossRefGoogle Scholar
  151. 151.
    Hu Y, Liu J, Wang J, Liu Q. (2011) The controversial links among calorie restriction, SIRT1, and resveratrol. Free Radic. Biol. Med. 51:250–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. (2001) Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem. 276:38837–43.PubMedCrossRefGoogle Scholar
  153. 153.
    Alcain FJ, Villalba JM. (2009) Sirtuin activators. Expert Opin. Ther. Pat. 19:403–14.PubMedCrossRefGoogle Scholar
  154. 154.
    Mai A, et al. (2005) Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J. Med. Chem. 48:7789–95.PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Department of NephrologyThe Second Hospital of Jilin UniversityChangchunChina
  2. 2.Kosair Children’s Hospital Research Institute, Department of PediatricsUniversity of LouisvilleLouisvilleUSA
  3. 3.Department of Pharmacology and ToxicologyUniversity of LouisvilleLouisvilleUSA

Personalised recommendations